Drug allergy/hypersensitivity[@R1] is a common problem seen by general and subspecialty adult and pediatric outpatient clinics,[@R2] inpatient wards,[@R3] and emergency department.[@R4] Among specialists, patients with drug allergy/hypersensitivity may present to an allergologist,[@R5] dermatologist, or other organ-based specialist depending on the type, extent, and severity[@R6; @R7; @R8; @R9] of clinical manifestations. Although guidelines for the diagnosis, evaluation, and treatment of drug allergy/hypersensitivity have been available for more than a decade, clinical practice is heterogenous across the world and indeed even within districts/regions in the same country. This may be influenced by different origins of undergraduate and postgraduate allergological training (dermatology, pulmonology, or allergy/immunology[@R10; @R11]), type of allergological practice (private, government practice, clinical or research-based institution), funding mechanisms, accessibility to various types of diagnostic tests, availability of basic versus tertiary practice infrastructure/laboratory equipment, and many other factors.[@R12]

OBJECTIVE {#s1}
=========

The objective of this survey was to study the diagnostic and treatment modalities used in drug allergy/hypersensitivity among members of the World Allergy Organization (WAO), with the results forming the framework for developing the educational and training needs and for improving access to drug allergy diagnostic and treatment modalities across WAO member societies. The specific aims of this survey wereTo increase the global awareness on the requirement of specialized/dedicated allergy clinics/centers for drug allergy testing and management;To lay foundations toward a globally standardized clinical practice of drug allergy management;To train allergists in performing diagnostic tests;To facilitate exchanges of knowledge and collaborations among allergy centers in different countries.

METHODS {#s2}
=======

The questionnaire was initiated and circulated to members of the WAO Drug Allergy Special Committee for evaluation in January 2009. The questions covered both diagnostic and therapeutic practices in drug allergy/hypersensitivity. The final questionnaire comprised a total of 39 questions, which was approved by the entire committee (Appendix 1).

The questionnaire was then converted into a Web-based questionnaire by the WAO Secretariat and sent electronically to 77 regional and national member societies of WAO. If representatives of member societies were unable to complete the specific questions on diagnostic tests and therapies available in their own country/region, they were asked to recommend the questionnaire to centers that would be able to respond to the questions. All respondents were given 6 weeks (June 29, 2009 to August 9, 2009) to reply. The responses were then collated by the WAO Secretariat, and the numbers and percentages of respondents for each question were collated.

RESULTS {#s3}
=======

There were a total of 82 responses comprising respondents from WAO member societies (95%), associate member societies (3.7%), regional organizations (3.7%), and affiliate organizations (1.1%). There were 13 additional responses from individuals who were recommended by the WAO member society representative who was not able to complete the specific questions on diagnostic tests and therapies available in the country/region. The geographical origin of all respondents was Europe (49.1%), Asia Pacific (26.4%), Latin America (15.1%), North America (5.7%), and Africa/Middle East (3.7%).

Among all responders, 95.3% and 55.6% responded that dedicated allergy clinics and dermatology clinics, respectively, in their country conducted evaluations for drug allergy/hypersensitivity. Among responders, 61.8% practiced in countries/regions where there were drug allergy centers/clinics dedicated to adult care, and 64.7% practiced where such centers dedicated to pediatric care were available.

The most widely used clinical practice guideline was the American Academy of Allergy Asthma and Immunology/American College of Allergy, Asthma and Immunology (AAAAI/ACAAI) 2008 Practice Parameter Update: Allergy diagnostic testing[@R13] (59.7%), followed by the European Academy of Allergy Asthma and Clinical Immunology (EAACI) guidelines on provocation tests for aspirin and other drugs[@R14; @R15] (41.6%). The remaining guidelines used[@R16; @R17; @R18; @R19; @R20; @R21; @R22; @R23; @R24; @R25; @R26] are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Commonly Used Clinical Guidelines

![](waoj-4-257-t001)

For immediate reactions, skin testing was used by 74.7%, with the majority (67.6%) using this for both clinical care and research. Only 71.4% had access to penicillin skin test reagents, where the commercial Diater product for penicilloyl polylysine and minor determinant mix was used by 49.1% and in-house reagents by 26.3%. Drugs that were commonly skin tested were penicillins (87.5%), cephalosporins (77.8%), local anesthetic agents (75.0%), general anesthetic agents (61.1%), and non--beta-lactam antibiotics (50.0%) ([Table 2](#T2){ref-type="table"}). Drugs for skin testing were prepared by the allergist in 65.3%, nurse practitioner/specialist in 34.7%, and pharmacist in 27.8%. Among some respondents, there was more than 1 practitioner who could prepare the drugs for skin testing. Negative skin tests were followed by a drug provocation test (DPT) in only 56.2% of cases.

###### 

Drugs Commonly Skin Tested
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In vitro--specific IgE tests were used by 67.4% of respondents. The tests commercially available were the immunoCAP-fluorescent enzyme immunoassay (CAP-FEIA) (previously Pharmacia now called Phadia) in 80.6%, radioallergosorbent test (RAST) in 56.5%, flow cytometric cellular allergen stimulation test (Buhlmann Labs) in 25.8%, cellular allergen stimulation test enzyme-linked immunosorbent assay (CAST-ELISA) (Buhlmann Labs) in 24.2%, and flow cytometry-2-cellular allergen stimulation test (Flow-2-CAST) (Buhlmann Labs) in 14.5% ([Table 3](#T3){ref-type="table"}). In-house assays most commonly used were radioallergosorbent test (48.6%) and radioimmunoassays (22.9%). The most commonly tested drugs were penicillins (93.7%), cephalosporins (61.9%), general anesthetic agents (36.5%), and nonsteroidal anti-inflammatory drugs (NSAID) (27.0%). Other tests available to respondents included serum total tryptase in 75.0% and basophil activation test in 54.4%.

###### 

Commercially Available In Vitro--Specific IgE Tests
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For nonimmediate reactions, lymphocyte transformation tests (LTTs) were used by 36.8% of respondents, the majority for both clinical care and research (48.6%) but more for research (37.1%) than for clinical care (14.3%) alone. Where available, in-house LTT was used by 52.9%, sent to another facility in the same region/country by 32.4%, and sent out of the region/country by 14.7%. The drugs most commonly tested using LTT were beta-lactam antibiotics (77.8%), non--beta-lactam antibiotics (58.3%), and NSAID/selective cyclooxygenase inhibitors (36.1%). The other drugs commonly tested are listed in [Table 4](#T4){ref-type="table"}. The types of nonimmediate reactions most commonly tested using LTT were drug-induced hypersensitivity syndrome (DIHS) (65.6%), Stevens--Johnson syndrome (SJS) (65.6%), maculopapular exanthema (46.9%), acute generalized exanthematous pustulosis (AGEP) (46.9%), and toxic epidermal necrolysis (TEN) (46.9%). The other types of nonimmediate reactions commonly tested using LTT are shown in [Table 5](#T5){ref-type="table"}.

###### 

Drugs Commonly Tested Using LTT
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###### 

Types of Nonimmediate Reactions Commonly Tested Using LTT
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Patch tests were used for both clinical care and research (59.6%) but more for clinical care (30.8%) than for research (9.6%) alone. Commercialized form of the drug was used by 55.3%, the pure substance by 21.3%, and both by the remaining 23.4%. The most common dilutions were 1% (34.2%) and 5% (31.6%), with majority using petrolatum (90.0%). Drugs used for patch testing were obtained commercially by 55.3%, prepared in-house by 34.0%, and obtained from both sources in the remaining 10.7%. In addition to the parent drug, 53.3% also tested components other than the parent drug including preservative (44.4%), coloring (37.8%), and excipient (28.9%). Patch test reading was done, and read at 20 minutes by 4.2%, 48 hours by 47.9%, 96 hours by 10.4%, and on day 7 (if days 2 and 4 are negative) by 37.5%. Photopatch tests were done by only 46.5% of respondents. Drugs most commonly used for patch testing were beta-lactam antibiotics (83.3%), non--beta-lactam antibiotics (64.6%), and corticosteroids (60.4). The drugs commonly patch tested are shown in [Table 6](#T6){ref-type="table"}. Patch tests were most commonly used in the diagnosis of maculopapular exanthema (66.0%), DIHS (63.8%), fixed drug eruption (61.7%), and AGEP (55.3%). The other types of nonimmediate reactions for which patch tests were commonly used are shown in [Table 7](#T7){ref-type="table"}.

###### 

Drugs Commonly Tested Using Patch Tests
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###### 

Types of Nonimmediate Reactions Commonly Tested Using Patch Tests
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DPTs were used by 68.4% with the most common indication being to exclude hypersensitivity where the history was not suggestive or the symptoms not specific for drug hypersensitivity/allergy (76.9%). It was used for definitive diagnosis where history was suggestive but allergological tests were negative, nonconclusive or not available by 67.7%; to exclude cross-reactivity of related drugs in proven hypersensitivity (eg, cephalosporin in a penicillin allergic individual) by 63.1%; and to provide safe pharmacologically/structurally nonrelated drugs in proven hypersensitivity (e.g. beta-lactams) by 60.0%. This is summarized in [Table 8](#T8){ref-type="table"}. Preparation of drugs for challenges was performed by the doctor (62.1%), pharmacist (39.4%), and nurse practitioner (25.8%), respectively. Challenges used were most commonly open challenges (75.4%), followed by single-blind placebo-controlled (44.6%), or double-blind placebo-controlled (24.6%). Oral challenges were more commonly used compared with parenteral challenges. Among oral challenges, the most commonly used formulations were tablet (80%), capsule (73.8%), or syrup (61.5%). Among parenteral challenges, subcutaneous challenges (49.2%) were more commonly done compared with intravenous (27.7%) and intramuscular (21.5%) routes.

###### 

Indications for DPTs
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In the survey on therapies for drug allergy, rapid desensitizations for the treatment of IgE-mediated and non--IgE-mediated anaphylactic reactions to chemotherapy, antibiotics, or biologic agents, such as monoclonal antibodies, were used by 69.6% of respondents. Systemic corticosteroids were used by 72.3% for the treatment of SJS and/or systemic manifestations of TEN, high-dose intravenous immunoglobulins for TEN by 50.8%, and other immunosuppressive drugs by 9.2% (most commonly cyclosporine). Comanagement with an intensive care/high-dependency/burns unit was commonly practiced by 67.7% of respondents, whereas comanagement with an ophthalmologist (49.2%), daily pain assessment and management (36.9%), and the use of the Severity of Illness Score for TEN for prognostication during the first 24 hours (29.2%) were less frequently practiced.

Human leukocyte antigen (HLA) testing for specific drugs associated with severe cutaneous adverse reactions (SCAR) before prescription was reported by 14 respondents (17.1%). Of these, 92.9% of respondents from the American, Australasian, Austrian, Azerbaijan, Chilean, Columbian, Dutch, French, and Swiss societies screened for HLA-B\*5701 in white ancestry before the prescription of abacavir. There were 21.4% of respondents from the Australasian, Chinese, and Dutch societies who screened for HLA-B\*1502 in Han Chinese or people with Asian ancestry before the prescription of carbamazepine. None of the respondents screened for HLA-B\*5801 before the prescription of allopurinol in Han Chinese.

DISCUSSION {#s4}
==========

There was a good response rate for this survey, reflecting significant interest in the diagnosis and management of drug allergy/hypersensitivity among WAO member organizations. Most regions used existing guidelines and practice parameters from their own (where available) and those from other international allergy/immunology member groups and regional organizations.

There were more respondents who did not have dedicated pediatric drug allergy services in their region compared with adult drug allergy clinics. First, this could be due to children with drug allergy/hypersensitivity being usually seen within general pediatric or general pediatric allergy clinics, in contrast to adult internal medicine/specialty services, which tend to be more subspecialized. Second, most clinical and research groups in pediatric allergology tend to focus more on pediatric asthma, eczema, rhinitis, food allergy, and anaphylaxis rather than drug allergy/hypersensitivity[@R27; @R28; @R29; @R30; @R31]. Third, children present, in general, with less complex drug-related allergies than adults because they do not tend to take many drugs at the same time. Although the principles of when and how to evaluate children with suspected drug allergy is no different from adults,[@R32; @R33] pragmatically, testing in children is mainly recommended if no alternative drug is available and there is an absolute requirement for that specific drug to be administered. There are logistic constraints as intradermal testing and DPTs may be difficult to perform on children, especially the very young. Even if drug allergy is documented in childhood, full retesting is often necessary once the adult age is reached. This pragmatic approach has not, however, reached unanimous consensus among allergists.

Skin tests (74.7%) and in vitro blood tests (67.4%) were commonly used in the diagnosis of immediate reaction, with beta-lactam antibiotics and anesthetic agents being the most commonly tested. However, only 70% of respondents had access to penicillin skin test reagents. Benzylpenicilloyl-polylysine, a major penicillin skin test reagent commercially known in the United States as, was not commercially available after September 2003. Hollister-Stier, the sole producer of PrePen in the United States, was directed by the Food and Drug Administration to cease its production in 2003 because of the lack of a dedicated penicillin manufacturing facility and hence quality concerns. A product containing major and minor determinants (Allergopen) was available on the European market until 2004, then it was also withdrawn by Merck worldwide.[@R17] Thus, major and minor penicillin determinants produced commercially by Diater S.A. (Madrid, Spain) were used in several European and Asian countries with comparable performance characteristics compared with PrePen and Allergopharma kit.[@R34; @R35; @R36; @R37] In September 2009, ALK-Abelló and AllerQuest, LLC announced the return of PrePen to the United States and the international market. With this, penicillin skin testing is likely to become more widely available among WAO member societies again.

Although intradermal tests (IDTs) are used in the diagnosis of immediate reactions,[@R13] the delayed IDT reading usually at 24 hours and 72 hours is useful in the diagnosis of nonimmediate reactions[@R38] and has been recommended in guidelines on the evaluation of drug allergy,[@R16] for instance, for nonimmediate reactions to beta-lactam antibiotics.[@R18] However, this survey did not look specifically at the number of sites that carried out delayed IDT readings.

For nonimmediate reactions, patch tests were used more commonly (54.7%) compared with LTT (36.8%). The use of patch tests and LTT is more common in Europe compared with other regions of the world. A positive patch test or LTT is useful, but a negative test cannot exclude drug allergy/hypersensitivity. Patch tests preparations are not well standardized across all drugs, seem to be useful only in certain types of drug eruptions (eg, exanthema, eczema, and AGEP) but not others (eg, TEN), and are useful only with certain drugs.[@R38; @R39] The same is true for LTT, which has been found to be useful in exanthema, AGEP, bullous exanthema, drug rash with eosinophilia and systemic symptoms, and only for certain drugs. Many of the respondents, mainly from Europe, used patch tests and LTT in diagnosing the putative drug for severe reactions (SJS, TEN, DIHS). The many disadvantages for LTT including the requirement for sterile cell cultures, long time required to run the test, use of radioactivity, and expensive equipment limit its use to specialized tertiary clinical and research centers.[@R40]

DPTs were used by 68.4% of respondents with the most common indication being to exclude hypersensitivity where the history was not suggestive or the symptoms not specific for drug hypersensitivity/allergy (76.9%). DPT is generally safe when properly carried out under supervision and with constant, careful patient assessment[@R41] both in adults[@R42] and in children.[@R43] It is most commonly used in the definitive diagnosis of beta-lactam (penicillin or cephalosporin) allergy,[@R44; @R45; @R46] or demonstration of tolerance to alternative NSAIDs---weak COX-1 inhibitors (paracetamol) and/or preferential (meloxicam) or highly selective COX-2 inhibitors (etoricoxib, parecoxib)---in patients with NSAID/aspirin exacerbated respiratory disease, urticaria/angioedema, or NSAID intolerance.[@R47; @R48; @R49; @R50; @R51]

Definitive treatment of drug allergy includes avoidance of the drug in question, patient education on prevention, knowledge of potentially cross-reacting drugs, and giving patients some form of medic alert identification or notification. The survey looked at 2 specific treatment modalities: drug desensitization and management of SCAR (SJS/TEN/DIHS).

Rapid desensitizations, carried out by 69.6% of respondents, has been described for the treatment of IgE-mediated and non--IgE-mediated anaphylactic reactions to chemotherapy, antibiotics, or biologic agents, such as monoclonal antibodies,[@R52; @R53; @R54] and to high-dose aspirin in aspirin exacerbated respiratory disease[@R55] and low-dose aspirin (desensitization rechallenge) in patients with coronary artery disease requiring percutaneous coronary intervention.[@R56; @R57; @R58]

The management of SJS/TEN[@R59] was variable across different respondents, among whom 72.3% used systemic corticosteroids in SJS and/or systemic manifestations of TEN, 50.8% used high-dose intravenous immunoglobulin for TEN and 9.2% used other immunosuppressive drugs including cyclosporine. More than two thirds would consider comanaging TEN patients with an intensivist/ burns unit[@R60; @R61]; this may have been limited by the availability of such tertiary specialty care in certain regions. Only 49.2% considered comanagement with an ophthalmologist, suggesting that a greater awareness of the ocular complications of SCAR and the need for aggressive ocular immunomodulatory therapy may be needed.[@R62]

HLA screening[@R63] has been shown to be useful in preventing SCAR before the prescription of abacavir in whites,[@R64] carbamazepine in Han Chinese or individuals of Asian ancestry,[@R65] and allopurinol in Han Chinese.[@R66] Only 17.1% of respondents had access to HLA screening for drugs at high risk of causing SCAR, with the majority (92.9%) screening for HLA B\*5701 before prescribing abacavir, and 21.4% screening for HLA B\*1502 before prescribing carbamazepine in Asians. This may have been due to lack of availability of rapid HLA screening kits in certain parts of Asia, or differences in local pharmacovigilance requirements.[@R67]

There were several limitations to this survey, which was highlighted by respondents. First, within large countries/regions, the president/chair of the WAO affiliated society may not have had ample opportunity to run the survey through all members from different states/districts within the 6-week consultation period, especially where practices may be heterogenous and in large countries/regions. Second, interest and expertise in dealing with drug allergies also varied within different countries/regions, as certain types of drug allergies were looked after by organ-based specialists rather than allergologists, for example, patients with SJS were looked after by dermatologists in certain regions. In this context, the survey may have inevitably been slightly skewed toward obtaining/ receiving the results from the most dedicated centers with specific research interests. For example, the use of basophil activation test or LTT as diagnostic tools may not be as common in clinical practice as it appears from the audit\'s results. Third, there were clinical practices in certain regions, which were not covered by the questions used in the survey (eg, delayed IDT readings for nonimmediate reactions).

Although this survey has shown the types of tests available and practiced in various parts of the world, this need not necessarily mean that the tests are uniformly useful. For instance, patch tests, although carried out in many European centers for nonimmediate reactions, are drug-specific and reaction-specific and thus are more useful where certain types of nonimmediate reactions predominate. The use of standardized nomenclature, patient profiles, harmonization of test procedures, measurements, and outcome measures are crucial in improving the diagnostic modalities presently used in evaluating drug hypersensitivity/ allergy, findings similarly reflected in the Drug Ambassador Project carried out by the European Network for Drug Allergy.[@R68]

CONCLUSIONS {#s5}
===========

This survey shows that even though well-established international guidelines are available for the diagnosis and management of drug allergy, practices vary across the different regions of the world due to differences in allergology training, practice setups, funding mechanisms, and resource limitations. Nonetheless, the results of this survey will help facilitate multicenter networking in education, practice, and resource development in drug allergy/hypersensitivity. It is our hope that the results of this survey will, through WAO, facilitate clinical, educational, and research collaboration among the different allergy centers with an interest in drug allergy/hypersensitivity.
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